Skip to main content
Top
Published in: Cancer Cell International 1/2020

01-12-2020 | Radiotherapy | Primary research

Baicalin reverses radioresistance in nasopharyngeal carcinoma by downregulating autophagy

Authors: Cong Wang, Yinli Yang, Lining Sun, Jing Wang, Zhansheng Jiang, Yanwei Li, Dongying Liu, Haiyan Sun, Zhanyu Pan

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Radiation resistance is the main cause of recurrence after radiotherapy, and increased autophagy after radiotherapy is related to radiotherapy resistance. This study aims to investigate the reversal effect of baicalin on radioresistance and its related mechanism.

Methods

CCK-8 and flow cytometry were used to detect the effect of proliferation and apoptosis by baicalin. Clone formation test was used to verify the effect of baicalin radiosensitization. Western blot analysis and electron microscopy were employed to observe the effect of baicalin on autophagy.

Results

Compared with the radiation therapy (RT) group, the RT combined baicalin (RT + BA) group showed a significantly low 2 Gy survival fraction of radiation therapy (P < 0.05). LC3-II protein expression in the RT group was significantly higher than which in the RT + BA group (P < 0.05). Electron microscopy showed that more autophagic vacuoles were observed in the RT group than those in the RT + BA group.

Conclusions

Overall, baicalin can reverse the radioresistance of human nasopharyngeal carcinoma CNE-2R cells by downregulating RT-enhanced autophagy.
Literature
1.
go back to reference Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef
2.
go back to reference Razak AR, et al. Nasopharyngeal carcinoma: the next challenges. Eur J Cancer. 2010;46(11):1967–78.CrossRef Razak AR, et al. Nasopharyngeal carcinoma: the next challenges. Eur J Cancer. 2010;46(11):1967–78.CrossRef
3.
go back to reference Frikha M, et al. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02). Ann Oncol. 2018;29(3):731–6.CrossRef Frikha M, et al. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02). Ann Oncol. 2018;29(3):731–6.CrossRef
4.
go back to reference Fulda S. Targeting autophagy for the treatment of cancer. Biol Chem. 2018;399(7):673–7.CrossRef Fulda S. Targeting autophagy for the treatment of cancer. Biol Chem. 2018;399(7):673–7.CrossRef
5.
go back to reference Codogno P. Shining light on autophagy. Nat Rev Mol Cell Biol. 2014;15(3):153.CrossRef Codogno P. Shining light on autophagy. Nat Rev Mol Cell Biol. 2014;15(3):153.CrossRef
6.
go back to reference Liang ZG, et al. The role of autophagy in the radiosensitivity of the radioresistant human nasopharyngeal carcinoma cell line CNE-2R. Cancer Manag Res. 2018;10:4125–34.CrossRef Liang ZG, et al. The role of autophagy in the radiosensitivity of the radioresistant human nasopharyngeal carcinoma cell line CNE-2R. Cancer Manag Res. 2018;10:4125–34.CrossRef
7.
go back to reference Li-Weber M. New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin. Baicalein Baicalin Cancer Treat Rev. 2009;35(1):57–68.CrossRef Li-Weber M. New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin. Baicalein Baicalin Cancer Treat Rev. 2009;35(1):57–68.CrossRef
8.
go back to reference Hs J, et al. Antiallergic effects of Scutellaria baicalensis on inflammation in vivo and in vitro. J Ethnopharmacol. 2012;141(1):345–9.CrossRef Hs J, et al. Antiallergic effects of Scutellaria baicalensis on inflammation in vivo and in vitro. J Ethnopharmacol. 2012;141(1):345–9.CrossRef
9.
go back to reference Lai W, et al. Baicalin hydrate inhibits cancer progression in nasopharyngeal carcinoma by affecting genome instability and splicing. Oncotarget. 2018;9(1):901–14.CrossRef Lai W, et al. Baicalin hydrate inhibits cancer progression in nasopharyngeal carcinoma by affecting genome instability and splicing. Oncotarget. 2018;9(1):901–14.CrossRef
10.
go back to reference Ko A, et al. Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death Differ. 2014;21(1):92–9.CrossRef Ko A, et al. Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death Differ. 2014;21(1):92–9.CrossRef
11.
go back to reference Bx L, et al. The regulatory effects of autophagy to the CNE2 cells radio-sensitization. Cell Mol Biol. 2016;62(13):12–4.CrossRef Bx L, et al. The regulatory effects of autophagy to the CNE2 cells radio-sensitization. Cell Mol Biol. 2016;62(13):12–4.CrossRef
12.
go back to reference Zhu HY, et al. Baicalin inhibits autophagy induced by influenza A virus H3N2. Antiviral Res. 2015;113:62–70.CrossRef Zhu HY, et al. Baicalin inhibits autophagy induced by influenza A virus H3N2. Antiviral Res. 2015;113:62–70.CrossRef
Metadata
Title
Baicalin reverses radioresistance in nasopharyngeal carcinoma by downregulating autophagy
Authors
Cong Wang
Yinli Yang
Lining Sun
Jing Wang
Zhansheng Jiang
Yanwei Li
Dongying Liu
Haiyan Sun
Zhanyu Pan
Publication date
01-12-2020
Publisher
BioMed Central
Keyword
Radiotherapy
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-1107-4

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine